鼻窦鳞状细胞癌 (SqCC) 经常侵犯眼眶。鼻窦癌侵入眼眶的治疗方法可能因医疗中心和侵入程度而异。最终的治疗策略，无论是否涉及保留眼眶，都会根据具体情况而有所不同，并导致不同的结果。目前，鼻窦癌经常采用多模式治疗方法，包括手术、化疗（CTx）、放疗（RT）或同步放化疗（CCRT）。本研究旨在从不同角度评估侵犯眼眶的鼻窦 SqCC 的预后。我们对 2009 年至 2018 年间接受治疗的原发性鼻窦 SqCC 侵犯眼眶的患者进行回顾性分析。我们检查了肿瘤范围、眼眶侵犯、治疗策略、复发率和生存率。根据眼眶侵犯的级别，总生存 (OS) 和无病生存 (DFS) 率没有显着差异。当肿瘤切除并保留眼眶作为最终治疗时，与手术不是最终治疗（RT、CCRT）的情况相比，DFS 显着更长。接受眼眶切除术的患者与接受肿瘤切除并保留眼眶作为根治性治疗的患者之间的 DFS 没有显着差异。肿瘤切除并保留眼眶作为根治性治疗似乎是首选方法，可在确保生存的同时延长 DFS SqCC 伴眼眶侵犯的病例。

Sinonasal squamous cell carcinoma (SqCC) often invades the orbit. Treatment of sinonasal cancer invading orbit can vary depending on the medical center and the extent of the invasion. The definitive treatment strategy, whether it involves preserving the orbit or not, varies on a case-by-case basis and leads to different outcomes. Currently, a multimodal treatment approach, which includes surgery, chemotherapy (CTx), radiotherapy (RT), or concurrent chemoradiotherapy (CCRT), is frequently employed for sinonasal cancers. This study aims to evaluate the prognosis of sinonasal SqCC with orbit invasion in various perspectives.We conducted a retrospective review of patients with primary sinonasal SqCC invading the orbit who were treated at between 2009 and 2018. We examined factors such as the extent of tumor, orbit invasion, treatment strategies, recurrence rates, and survival rates.Overall survival (OS) and disease-free survival (DFS) rates did not significantly differ based on the grade of orbit invasion. When tumor resection with orbit preservation was performed as definitive treatment, DFS was significantly longer compared to cases where surgery was not the definitive treatment (RT, CCRT). There was no significant difference in DFS between those who underwent orbit exenteration and those who underwent tumor resection with orbit preservation as the definitive treatment.Tumor resection with orbit preservation as the definitive treatment appears to be the preferred approach, leading to prolonged DFS while ensuring survival in cases of SqCC with orbit invasion.